IND-enabling studies

Paris, France, April 7, 2026 Phase 2 Success Across Respiratory Indications In a major advancement for respiratory disease therapeutics,...

KANAGAWA, Japan, Dec. 17, 2025 — PeptiDream Inc. announced promising pre-clinical results for a novel oral dual IL-17A and...